Trial Profile
A Phase 4, Randomized, Double-Blind, Study Evaluating the Safety, Efficacy and Pharmacokinetics of Idelalisib in Patients with Previously Treated Follicular Lymphoma or Small Lymphocytic Lymphoma
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 17 Jun 2016
Price :
$35
*
At a glance
- Drugs Idelalisib (Primary)
- Indications Follicular lymphoma; Lymphoma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 17 May 2016 Status changed from recruiting to discontinued.
- 29 Jan 2016 New trial record